ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,226.86
-1.07%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.7255
0.03%
Brent Oil
83.655
-0.13%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NYSE
  6. Takeda Pharmaceutical Company Ltd (TAK)

  7. Takeda Pharmaceutical Company Ltd (TAK) ニュース

TAK

Takeda Pharmaceutical (TAK)

Takeda Pharmaceutical Company Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:TAK
日付受信時刻ニュースソース見出しコード企業名
2024/05/1621 : 02PR Newswire (Canada)Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infectionNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/05/1621 : 02PR Newswire (Canada)Takeda Canada Inc. conclut une lettre d'intention avec l'Alliance pancanadienne pharmaceutique (APP) concernant LIVTENCITY® (maribavir) pour le traitement des adultes greffés atteints d'une infection à cytomégalovirus (CMV)NYSE:TAKTakeda Pharmaceutical Company Ltd
2024/05/1421 : 00Business WireTakeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual MeetingNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/05/1020 : 03Business WireTakeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire...NYSE:TAKTakeda Pharmaceutical Company Ltd
2024/05/1006 : 07Business WireTakeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023, liefert Ausblick auf das GJ 2024, und bekräftigt Bekenntnis zur Pipeline-Entwicklung in der späten Entwicklungsphase sowie zur Steigerung der operativen GewinnmargeNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/05/0915 : 07Business Wire武田薬品工業: 2023年度通期業績および2024年度の見通しを公表 - 後期段階のパイプライン開発とCore営業利益率改善へのコミットメントを強調NYSE:TAKTakeda Pharmaceutical Company Ltd
2024/05/0915 : 07Business WireTakeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin ExpansionNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/04/2621 : 30Business WireTakeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal CancerNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/04/2621 : 30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/04/2320 : 00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/04/2217 : 10PR Newswire (US)Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery ProgramsNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/04/1908 : 00Business WireU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s DiseaseNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/04/0821 : 00Business WireTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional FoodNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2721 : 56PR Newswire (US)Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAENYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2721 : 53PR Newswire (US)Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAENYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2714 : 01Business WireTakeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekanntNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2714 : 01Business WireTakeda annonce les candidats au conseil d’administration pour la prochaine assemblée générale des actionnairesNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2708 : 07Business Wire武田薬品工業: 第148回定時株主総会に提案する取締役候補者についてNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2708 : 07Business WireTakeda Announces Candidates for Board of Directors at Upcoming Shareholders MeetingNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2621 : 00Business WireTakeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)NYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2122 : 39Business Wire武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®（ポナチニブ）の医薬品承認事項変更申請（sNDA）について、FDAからの承認取得を発表NYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2116 : 33Business WireTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch die FDA bei erwachsenen Patienten mit neu diagnostizierter Ph+ ALLNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2104 : 18Business WireTakeda annonce l'approbation par la FDA des États-Unis d'une demande supplémentaire de nouveau médicament (sNDA) pour ICLUSIG ® (ponatinib) chez les patients adultes atteints de leucémie lymphoblastique aiguë (LAL Ph+) nouvellement diagnostiquéeNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/2001 : 20Business WireTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALLNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/1919 : 30GlobeNewswire Inc.CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/03/1321 : 00Business WireTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune ThrombocytopeniaNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/02/2821 : 03Business Wire武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力NYSE:TAKTakeda Pharmaceutical Company Ltd
2024/02/2807 : 26Business WireTakeda et Biological E. Limited s’associent pour accélérer l’accès au vaccin contre la dengue dans les zones endémiquesNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/02/2721 : 38Business WireTakeda und Biological E. Limited arbeiten zusammen, um den Zugang zu Dengue-Impfstoff in endemischen Gebieten zu beschleunigenNYSE:TAKTakeda Pharmaceutical Company Ltd
2024/02/2713 : 30Business WireTakeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic AreasNYSE:TAKTakeda Pharmaceutical Company Ltd
 Showing the most relevant articles for your search:NYSE:TAK

最近閲覧した銘柄

TG
0PV2
Moovly Media
BIT
P1ORO7
BNP Paribas Issuance
GATE
EGGETH
Goose Golden Egg
BIT
P1LK70
BNP Paribas Issuance
UNSW
SUNIETH
SuniToken
BIT
SBDUS5
Societe Generale Effekten
BIT
F38013
Vontobel Financial Produ...
BIT
P1P2X2
BNP Paribas Issuance
ASX
GC1PA
Glennon Small Companies
TSXV
CMX
Chilean Metals
BIT
F32217
Vontobel Financial Produ...
BFNX
RTEETH
BIT
STRN5L
Societe Generale Effekten
BIT
P1J8J6
BNP Paribas Issuance
BIT
F34597
Vontobel Financial Produ...
BIT
P1TXI6
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有